A multi-disciplinary association of healthcare professionals who provide care for individuals with haemophilia and other bleeding disorders.
🌐 www.eahad.org
📚 https://academy.eahad.org/eahad
EAHAD - European Association for Haemophilia and Allied Disorder
Loading...
Hereditary Hemorrhagic Telangiectasia (HHT) affects around 1 in 5,000 people worldwide, yet it remains widely underdiagnosed. Early diagnosis is key to improving outcomes and quality of life for people living with HHT. 🎥 Watch the e-learning module w/ Raj Kasthuri: academy.eahad.org/eahad/2026/e...
⏳ Final Call! Join our upcoming webinar on Inhibitor Development in Gene Therapy for Haemophilia with Yesim Dargaud, Davide Matino, Sebastien Lacroix-Desmazes, Guy Young to explore these key issues.
📅 Monday | 17:00 CEST
🔗 Register now: academy.eahad.org/eahad/2026/g...
Are there identifiable patterns or risk factors emerging from real-world cases? Discuss the topic in our upcoming Gene Therapy webinar, which brings together expert perspectives from Yesim Dargaud, Davide Matino, Sébastien Lacroix-Desmazes, and Guy Young. 🔗 academy.eahad.org/eahad/2026/g...
Missed the Novo Nordisk symposium on Refocusing on haemophilia B: Patient-centric approaches to using anti-TFPI at EAHAD 2026? The full session is now available on the EAHAD Academy. Replay the session: academy.eahad.org/eahad/2025/n...
📣 EAHAD and @ehc-news.bsky.social come together once again, bringing together clinical perspectives, patient experiences, and interactive discussion to support a deeper understanding of Haemophilia B with inhibitors. Register now 🔗https://form.dragnsurvey.com/survey/r/b5590c21
🎥 Watch the new e-learning module featuring Raj S. Kasthuri on Hereditary Hemorrhagic Telangiectasia (HHT) to review the genetic basis, pathophysiology, clinical manifestations, diagnostic criteria, and current management strategies for HHT: academy.eahad.org/eahad/2026/e...
The Request for Proposals to host the Annual EAHAD Congress 2030 is now open! This is your chance to put your city in the spotlight and contribute to advancing care for patients across Europe. 🌍 Visit the EAHAD website for submission guidelines: www.eahad.org/request-for-... 🗓️ Deadline: 1 Jan 2027
📄Read the new publication on the JTH supported by the EAHAD Research Grants 2024: “Prothrombotic PROC variant rebalancing hemostasis in severe haemophilia A with attenuated bleeding risk”. Congratulations to the authors on this valuable contribution to the field. 🔗 www.jthjournal.org/article/S153...
📰 New real-world data from the Adelphi Real World Haemophilia Disease Specific Programme underline persistent unmet needs in haemophilia and the continued challenge of aligning treatment outcomes with patient priorities 🔗 @haemophilia_jnl onlinelibrary.wiley.com/doi/10.1111/...
Last few hours to register for our upcoming webinar on Inhibitor Development in Gene Therapy for Haemophilia ⏳ Join Yesim Dargaud, Davide Matino, Sébastien Lacroix-Desmazes, and Guy Young as they explore emerging insights in the field 🧬
🔗 Register now: academy.eahad.org/eahad/2026/g...
EAHAD - European Association for Haemophilia and Allied Disorder
EAHAD - European Association for Haemophilia and Allied Disorder
EAHAD - European Association for Haemophilia and Allied Disorder
EAHAD - European Association for Haemophilia and Allied Disorder
EAHAD - European Association for Haemophilia and Allied Disorder
EAHAD - European Association for Haemophilia and Allied Disorder
EAHAD - European Association for Haemophilia and Allied Disorder
EAHAD - European Association for Haemophilia and Allied Disorder
EAHAD - European Association for Haemophilia and Allied Disorder
EAHAD - European Association for Haemophilia and Allied Disorder
Introduction
Prophylactic factor replacement and non-factor therapy has improved bleed prevention and clinical outcomes for people with haemophilia (PwH). The remaining burdens faced by PwH in real-.....
Are you a clinician actively involved in the haemophilia and bleeding disorders field and a dedicated member of EAHAD? If so, we're happy to inform you that we've just launched the EAHAD 2030 Request ...
www.eahad.org
Severe hemophilia A (HA), defined by a clotting factor [F]VIII level of <1%, leads
to a severe bleeding tendency. A pathogenic F8 variant p.His300Lysfs∗41 accounted
for <1% FVIII levels in a patient w...
🧬 What do clinical trial data suggest about the long-term relevance of inhibitors in treated patients? Register for our upcoming webinar to hear expert discussion on emerging clinical data.
📅 15 June | 17:00 CEST
🔗 academy.eahad.org/eahad/2026/g...
EAHAD - European Association for Haemophilia and Allied Disorder
